U.S. Markets closed

Cynosure, Inc. (CYNO)

NASDAQ Global Select - NASDAQ Global Select Delayed Price. Currency in USD
Add to watchlist
65.97-65.97 (-100.00%)
People also watch
CUTRELOSHURNCNMDCPLA
Full screen
Previous Close65.97
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Can Anyone Challenge Allergan In Medical-Aesthetics Market?
    Investor's Business Daily5 months ago

    Can Anyone Challenge Allergan In Medical-Aesthetics Market?

    Fat freezing, ear-pinning, breast-enlarging Allergan isn't making expansion in the medical-aesthetics market.

  • Hologic Completes Cynosure Buyout, Boosts Core Business
    Zacks5 months ago

    Hologic Completes Cynosure Buyout, Boosts Core Business

    Hologic, Inc. (HOLX) recently announced the completion of it earlier declared acquisition of marketer of aesthetic treatment systems, Cynosure, Inc.

  • Zacks Small Cap Research5 months ago

    MRLB U.S. Sales Jump 38% As Aesthetic Market Heats Up

    Miramar Labs (MRLB) reported financial results for the fourth quarter and year ending December 31, 2016.  Revenue in Q4 came in at $4.4M, down 18% from the $5.3M generated in the comparable year-earlier period but up almost 3% from Q3 2016 ($4.3M).  On a yoy basis, miraDry console sales fell 24% ($2.4M Q4 ’16 vs. $3.1M Q4 ’15) while consumable sales fell 9% ($1.9M Q4 ’16 vs. $2.1M Q4 ’15).  Miramar attributes most of the yoy revenue decline to timing of Asia console sales, which were received earlier in the year in 2016 as compared to 2015.